Please login to the form below

Not currently logged in
Email:
Password:

Sanofi's Jez Moulding joins UDG Healthcare as COO

Will oversee its Ashfield division and have responsibility for the group's strategy

Jez MouldingHealthcare services provider UDG Healthcare has appointed Jez Moulding as its group chief operation officer and executive vice president.

Moulding will oversee its Ashfield division globally and have responsibility for group IT, quality, compliance, strategy and communications.

He said: “I am thrilled to be joining such a fast growing, dynamic team in Ashfield and UDG Healthcare.

“Ashfield has grown over many years and is a market leader in commercialisation services to global pharmaceutical clients.

“I look forward to building on this strong platform and driving further expansion across the group.”

Prior to UDG Healthcare, Moulding served Sanofi for 18 years holding numerous senior leadership positions such as senior VP and North American region head for diabetes and cardiovascular.

Brendan McAtamney, CEO at UDG Healthcare, said: “We are delighted to welcome Jez to UDG Healthcare and to Ashfield.

“He has extensive leadership experience in the pharmaceutical sector within our key global markets.

“His most recent experience leading the Sanofi North American business will be extremely valuable to us as we continue to develop our Ashfield US business and expand the group internationally.”

Moulding will succeed Chris Corbin who will transition to the role of chairman of Ashfield and will continue to serve as a non-executive director of UDG Healthcare.

25th April 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics